310 related articles for article (PubMed ID: 25307552)
1. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
[TBL] [Abstract][Full Text] [Related]
2. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Xu H; O'Gorman M; Tan W; Brega N; Bello A
Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
[TBL] [Abstract][Full Text] [Related]
3. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
4. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
Laille E; Patel M; Jones SF; Burris HA; Infante J; Lemech C; Liu L; Arkenau HT
J Clin Pharmacol; 2015 Dec; 55(12):1378-85. PubMed ID: 26053962
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
7. Lurasidone drug-drug interaction studies: a comprehensive review.
Chiu YY; Ereshefsky L; Preskorn SH; Poola N; Loebel A
Drug Metabol Drug Interact; 2014; 29(3):191-202. PubMed ID: 24825095
[TBL] [Abstract][Full Text] [Related]
8. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
[TBL] [Abstract][Full Text] [Related]
9. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
[TBL] [Abstract][Full Text] [Related]
13. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
[TBL] [Abstract][Full Text] [Related]
14. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
[TBL] [Abstract][Full Text] [Related]
16. Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
Zhi J; Zhai S; Georgy A; Liang Z; Boldrin M
J Clin Pharmacol; 2016 May; 56(5):548-54. PubMed ID: 26272330
[TBL] [Abstract][Full Text] [Related]
17. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
[TBL] [Abstract][Full Text] [Related]
18. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
[TBL] [Abstract][Full Text] [Related]
19. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
